| View |
|
BR-1088
|
Insulin Human (rDNA)
|
Insuget 70/30
|
100 IU/mL
|
Suspension for Injection (IM/SC)
|
-
|
Getz Pharma Pvt. Ltd.
|
Pakistan
|
-
|
22 October 2020
|
06 January 2025
|
| View |
|
BR-1089
|
Measles, Mumps, Rubella and Varicella Vaccine (Live)
|
Proquad
|
Each dose (0.5 mL) contains: Measles virus (Edmonston B) 3.00 log TCID50* Mumps virus (Jeryl Lynn B level)4.30 log TCID50
Rubella virus (Wistar RA 27/3) 3.00 log TCID50
Varicella virus (Oka/Merck) 3.99 PFU**
*50% Tissue Culture Infectious Dose
**Plaque Forming Units
|
Lyophilized Powder For Solution For Injection (SC)
|
Vaccines
|
Merck Sharp & Dohme LLC
|
U.S.A
|
Initial (from Monitored Release) [Correction]
|
11 March 2024
|
09 June 2025
|
| View |
|
BR-1091
|
Epoetin beta
|
Recormon
|
2,000 I.U./0.3mL
|
Solution for Injection (S.C./I.V.)
|
Antianemic Preparations
|
Roche Diagnostic GmbH
|
Germany
|
Renewal
|
18 September 2021
|
05 November 2026
|
| View |
|
BR-1093
|
Alteplase
|
Actilyse
|
50 mg
|
Powder for Solution for Infusion (IV
|
-
|
Boehringer Ingelheim Pharma GmbH & Co. KG
|
Germany
|
Initial (Variation)
|
19 September 2022
|
19 September 2027
|
| View |
|
BR-1096
|
Menothropin
|
Menopur
|
1200 IU
|
Lyophilized Powder For Injection (SC)
|
-
|
Ferring GmbH
|
Germany
|
-
|
18 March 2022
|
26 June 2025
|
| View |
|
BR-1098
|
Enoxaparin sodium
|
Lomoh-60
|
60 mg/0.6 mL
|
Solution for Injection (S.C.)
|
Antithrombotic Agent
|
Emcure Pharmaceuticals Ltd.
|
India
|
Renewal (Correction)
|
17 November 2023
|
30 June 2025
|
| View |
|
BR-1099
|
Enoxaparin Sodium
|
Lomoh - 40
|
40 mg/0.4 mL
|
Solution For Injection (S.C.)
|
-
|
Emcure Pharmaceuticals Ltd.
|
India
|
-
|
16 September 2021
|
30 June 2025
|
| View |
BR-1101_PI_01.pdf
|
BR-1101
|
Tocilizumab
|
Actemra
|
162 mg/ 0.9 mL
|
Solution For Injection (SC)
|
-
|
Vetter Pharma-Fertigung GmbH & Co. KG
|
Germany
|
-
|
08 March 2022
|
28 July 2025
|
| View |
|
BR-1102
|
Insulin Human (rDNA)
|
Insuget-N
|
100 IU/mL
|
Suspension for Injection (IM/SC)
|
-
|
Getz Pharma Pvt. Ltd.
|
Pakistan
|
-
|
22 October 2020
|
06 January 2025
|
| View |
|
BR-1103
|
Insulin Human (rDNA)
|
Insuget-R
|
100 IU/mL
|
Suspension for Injection (IM/IV/SC)
|
-
|
Getz Pharma Pvt. Ltd.
|
Pakistan
|
-
|
22 October 2020
|
06 January 2025
|
| View |
|
BR-1106
|
Insulin Human (rDNA)
|
SciLin R
|
100 IU/mL
|
Solution for Injection (IV/SC)
|
-
|
Bioton S.A.
|
Poland
|
-
|
26 February 2021
|
28 January 2025
|
| View |
|
BR-1107
|
Insulin Human (DNA)
|
Scilin R
|
100 IU/mL
|
Solution for Injection (IV/SC)
|
-
|
Bioton S.A.
|
Poland
|
Renewal
|
18 October 2021
|
28 January 2025
|
| View |
|
BR-1117
|
Heparin Sodium
|
Heprin
|
5000IU/mL
|
Solution For Injection (IV/SC)
|
-
|
Gland Pharma Limited
|
India
|
Renewal
|
14 May 2021
|
25 May 2025
|
| View |
|
BR-1121
|
Trastuzumab
|
Herceptin
|
600 mg/ 5 mL (120 mg/ mL)
|
Solution For Injection (SC)
|
-
|
F. Hoffmann-La Roche AG
|
Switzerland
|
Regular Renewal (Compliance)
|
07 March 2022
|
29 September 2025
|
| View |
|
BR-1122
|
Rituximab
|
Mabthera
|
1400 mg/ 11.7 mL
|
Solution For Injection (SC)
|
-
|
F. Hoffman-La Roche AG
|
Switzerland
|
Regular Renewal (Compliance)
|
18 February 2022
|
29 September 2025
|
| View |
|
BR-1123
|
Obinutuzumab
|
Gazyva
|
1 g/40 mL (25mg/mL)
|
Concentrate For Solution For Infusion (IV)
|
-
|
Roche Diagnostics GmbH
|
Germany
|
Initial (Variation)
|
12 August 2022
|
12 August 2027
|
| View |
BR-1125_PI_01.pdf
|
BR-1125
|
Quadrivalent Seasonal Influenza Vaccine (Split Virion,
Inactivated) Southern Hemisphere 2024 Strain.
|
Fluarix Tetra
|
Each dose (0.5 mL) contains the following influenza strains*:
A/Victoria/4897/2022 (H1N1)pdm09-like strain
(A/Victoria/4897/2022, IVR-238)
A/Thailand/8/2022 (H3N2)-like strain
(A/Thailand/8/2022, IVR-237)
B/Austria/1359417/2021-like strain
(B/Austria/1359417/2021, BVR-26)
B/Phuket/3073/2013-like strain
(B/Phuket/3073/2013, wild type) [Yamagata lineage] *Propagated in embryonated chicken eggs
**Haemagglutinin
15 μg of HA**
15 μg of HA**
15 μg of HA**
15 μg of HA**
|
Suspension for Injection (IM)
|
Vaccines
|
GlaxoSmithKline Biologicals NL Der SmithKline
|
Germany
|
Monitored Release (Strain Clearance)
|
19 February 2024
|
19 February 2025
|
| View |
|
BR-1126
|
Secukinumab
|
Cosentyx
|
150 mg/mL
|
Solution For Injection (SC)
|
-
|
Novartis Pharma Stein AG
|
Switzerland
|
Initial (from Monitored Release)
|
12 April 2022
|
06 January 2026
|
| View |
|
BR-1127
|
Secukinumab
|
Scapho
|
150 mg
|
Powder For Solution For Injection (SC)
|
-
|
Novartis Pharma Stein AG, Pharmaceutical
|
Switzerland
|
-
|
07 April 2022
|
14 January 2026
|
| View |
BR-1130_PI_01.pdf
|
BR-1130
|
Secukinumab
|
Scapho
|
150 mg/mL
|
Solution For Injection (Sc)
|
-
|
Novartis Pharma Stein AG, Pharmaceutical
|
Switzerland
|
Initial (from Monitored Release)
|
11 April 2022
|
06 January 2026
|